

## Oral Free Paper Sessions

10:00~17:00 on April 10 (Mon) 2017

At Room 2 “OHTORI B”, 1<sup>st</sup> Floor

### 10:00~10:30 Oral Free Paper Session: PBC

---

*Chair: Dr. Shinji Shimoda (Japan)*

**O-01. Dysfunctional DENND1B Induces T Cell Activation in PBC**

Yoshimi Kaise (Japan)

**O-02. Ras Inhibitors Suppress the Inflammatory Cytokine Production in T Cells of Primary Biliary Cholangitis**

Ryo Nakagawa (Japan)

**O-03. Asymptomatic and Symptomatic States are Independent Risk Factors Predicting PBC Long-term Outcome**

Satoru Joshita (Japan)

### 10:30~11:20 Oral Free Paper Session: Fibrosis

---

*Chair: Norifumi Kawada (Japan)*

**O-04. Involvement of Decreased IGF Production in Hepatocarcinogenesis and Hepatic Fibrosis among Patients with HCV-related Chronic Liver Disease**

Takashi Himoto (Japan)

**O-05. Serum Concentration of Galectin-9 Correlates to Liver Fibrosis**

Koji Fujita (Japan)

**O-06. Virus-induced IFN- $\lambda$  Cause Persistent Innate Immune Activation and Block IFN- $\alpha$  Signalling in HCV Infection**

Pil Soo Sung (Korea)

**O-07. Role of Cytoglobin in the Development of Liver Fibrosis and Cancer in Human and in a Mouse Model of Non-alcoholic Steatohepatitis**

Le Thi Thanh Thuy (Japan)

**O-08. Comparison of US Scoring System with MR Elastography in the Evaluation of Liver Stiffness and Steatosis**

Masaaki Shiina (Japan)

### 13:10~13:50 Oral Free Paper Session: HBV

---

*Chair: Yasuto Tanaka (Japan)*

**O-09. Hepatocellular Carcinoma (HCC) in the Japanese HBV Carrier Patients under 40**

Hiroshi Yotsuyanagi (Japan)

**O-10. Development and Validation of a Simple Score to Select HBV-infected Patients Eligible for Antiviral Therapy in Sub-Saharan Africa**

Yusuke Shimakawa (France)

**O-11. Androgen Receptor Affects the Expression of NKG2D Ligands in HBV-associated Human Hepatoma Cell Lines**

Koji Takahashi (Japan)

**O-12. Hepatitis B Virus Genome Analysis in Patients of Hepatocellular Carcinoma and Asymptomatic Carriers from Northern, Southern and North East India**

Premashis Kar (India)

**13:50~14:30 Oral Free Paper Session: Pathology**

---

*Chair: Masayoshi Kage (Japan)*

**O-13. Pathological Characteristics of Patients who Develop Hepatocellular Carcinoma after Sustained Virologic Response for Hepatitis C Virus Infection**

Kondo Reiichiro (Japan)

**O-14. Changes in Clinical and Histological Parameters Predictive of Liver Fibrosis and/or HCC Development after Direct-acting Antiviral Treatment for Chronic Hepatitis C**

Masaru Enomoto (Japan)

**O-15. Abnormal Hepatocellular Organelles Remain to be Observed in Sustained Virological Response Patients**

Haruyo Aoyagi (Japan)

**O-16. Risk Factors Associated with an Increase in Liver Stiffness in Patients with Type 2 Diabetes Mellitus: A Data-mining Analysis**

Takumi Kawaguchi (Japan)

14:30~14:40 Coffee Break

**14:40~15:30 Oral Free Paper Session: HCC Clinical-1**

---

*Chair: Keisuke Hino (Japan)*

**O-17. Consecutive Increment of Serum AFP Level is a Useful Surrogate Marker in Predicting HCC in Liver Cirrhosis Patients**

Si Hyun Bae (Korea)

**O-18. Hepatocellular Carcinoma Development in Hepatitis C Virus Patients Who Achieved Sustained Viral Response by Interferon Therapy and Direct Anti-viral Agents Therapy**

Yuko Nagaoki (Japan)

**O-19. Analysis of Developing HCC after Achieving SVR in Patients with DAAs Therapy for Hepatitis C**

Yasuhiko Nakao (Japan)

**O-20. Early Recurrence of Hepatocellular Carcinoma after Successful Therapy with Direct Acting Antiviral Agents for Chronic Hepatitis C: An Observational Study**

Mohamed Kohla (Egypt)

**O-21. Risk Factors for Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation: a Single Center Study**

Naoyuki Hino (Japan)

15:30~16:20 **Oral Free Paper Session: HCC Clinical-2**

---

*Chair: Yutaka Sasaki (Japan)*

- O-22. **Usefulness of Radiofrequency Ablation Training Program for Liver Tumors**  
Shuichiro Shiina (Japan)
- O-23. **Long-term Outcome of Liver Resection versus Transplantation for Resectable Hepatocellular Carcinoma in a Region where Living Donation Accounts for a Main Source**  
Pil Soo Sung (Korea)
- O-24. **Impact of Radiofrequency Ablation-induced Glisson's Capsule-associated Complications in Patients with Hepatocellular Carcinoma**  
Toru Wakamatsu (Japan)
- O-25. **Combination of Sorafenib with Transarterial Chemoembolization (TACE) Improves Survival as Compared to TACE Alone in Patients with Hepatocellular Carcinoma: A metaanalysis of 17 Studies**  
Ashish Kumar (India)
- O-26. **Initial Results of Patients with Intermediate and Advanced Hepatocellular Carcinoma Treated with Selective Internal Radiation Therapy (SIRT)**  
Dao Duc Tien (Vietnam)

16:20~17:00 **Oral Free Paper Session: Basic**

---

*Chair: Tsutomu Masaki (Japan)*

- O-27. **Regorafenib is a Promising Medicine for HCC Increasing Membrane-Bound MICA through ADAM 9 and 10 Suppression**  
Jun Arai (Japan)
- O-28. **Genome-wide Association Study-derived Immunometabolic Strategies for Management of Hepatocellular Carcinoma**  
Kaku Goto (Japan)
- O-29. **Epigenetic Regulation of CD133 and Chemosensitivity in Human HCC Cancer Stem Cells**  
Fanyin Meng (USA)
- O-30. **Role of JNK1 in Promotion of Hepatocarcinogenesis by Obesity: a Molecular Target for HCC Chemoprevention**  
Evi Arfianti (Indonesia)